You are now visiting tipharma.com.
On 1 January, 2016, TI Pharma and CTMM merged
to form a new organization called Lygature.
Please note that information on the tipharma.com site has not
been updated since, and is retained as an archive.
For up-to-date information, please visit lygature.org.
This project combines the expertise of the Dutch knowledge leaders in osteoarthritis (OA) to tackle this disease with unmet need from different angles at once. The proposed integrated approach allows for screening of novel molecules in a collection of unique tissues and disease models dealing with different aspects of the disease pathology; in parallel, molecules will be screened in inflammatory tests, as well as cartilage breakdown and generation assays, both in vitro and in vivo. In this way novel molecules are investigated efficiently for their ability to modify the disease. Sustained release of the novel molecules will be studied using novel biomaterials.
Project title: Potential disease-modifying drugs for Osteoarthritis
Short project title: OA all the way
Principal Investigator: Dr. Marco Eijken
Partners: Arcarios, Galapagos, DSM Biomedical, LUMC, TNO
Budget: 1.2 M EUR
Start: 1 January 2013
End: 30 June 2014
“Running public-private partnerships is a profession by itself. TI Pharma is an excellent example of how you can do this in an effective way.”
Director/Secretary of the Medicines Evaluation Board